Rumors of another major biosimilars deal are spreading after Korean media reported that Samsung Bioepis could be considering a bid for Biogen’s biosimilars business.
After Biogen indicated that it could be considering a sale of its biosimilars business, Korean media reports have pointed to Samsung Bioepis as a potential buyer. However, responding to the rumors in comments to Generics Bulletin, Samsung Bioepis declined to confirm that a deal was in the offing.
Biogen has made it clear for some time that it is considering selling its biosimilars business to a new owner,...
Melinta Therapeutics has prevailed at the Federal Circuit in a patent dispute over its reformulated intravenous antibiotic Minocin, with the appeals court upholding both infringement and validity and leaving Nexus Pharmaceuticals barred from launching a generic until 2031.
Mounjaro, Eliquis, and Darzalex buck the Q1 trend to make gains
The UK government has said it will invest almost £30m ($40.4m) in AI technologies to modernize the NHS and reduce wait times – but for the medtech sector, the devil will be in the details.
The UK government has said it will invest almost £30m ($40.4m) in AI technologies to modernize the NHS and reduce wait times – but for the medtech sector, the devil will be in the details.
Mounjaro, Eliquis, and Darzalex buck the Q1 trend to make gains
